BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 132 filers reported holding BRIDGEBIO PHARMA INC in Q3 2020. The put-call ratio across all filers is 0.69 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,197,066 | +128.0% | 45,395 | +44.3% | 0.00% | – |
| Q4 2021 | $525,000 | -94.0% | 31,467 | -83.1% | 0.00% | -100.0% |
| Q3 2021 | $8,739,000 | -4.2% | 186,438 | +24.6% | 0.00% | 0.0% |
| Q2 2021 | $9,121,000 | +83.9% | 149,649 | +85.9% | 0.00% | +50.0% |
| Q1 2021 | $4,959,000 | +113.5% | 80,506 | +146.4% | 0.00% | +100.0% |
| Q4 2020 | $2,323,000 | +132.1% | 32,671 | +6.4% | 0.00% | – |
| Q2 2020 | $1,001,000 | +0.5% | 30,700 | -10.6% | 0.00% | -100.0% |
| Q1 2020 | $996,000 | +255.7% | 34,339 | +330.0% | 0.00% | – |
| Q4 2019 | $280,000 | – | 7,986 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 6,068,125 | $100,609,513 | 48.41% |
| Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $514,990,899 | 15.50% |
| M28 Capital Management LP | 304,700 | $5,051,926 | 5.71% |
| Cormorant Asset Management, LP | 4,557,414 | $75,562 | 4.98% |
| Octagon Capital Advisors LP | 1,338,160 | $22,186,693 | 3.19% |
| Ikarian Capital, LLC | 594,686 | $9,859,894 | 2.24% |
| Affinity Asset Advisors, LLC | 389,800 | $6,462,884 | 2.13% |
| VIKING GLOBAL INVESTORS LP | 26,620,991 | $441,376,031 | 2.07% |
| Ikarian Capital, LLC | 549,600 | $9,112,368 | 2.07% |
| Affinity Asset Advisors, LLC | 320,000 | $5,305,600 | 1.75% |